---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023246"
form_type: "8-K"
ticker: "LFST"
cik: "0001845257"
company_name: "LifeStance Health Group, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:31:30.289277+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LifeStance Q3 rev +25% to $217.6M; cuts FY22 guidance on lower visits, higher health costs; CEO/CFO changes

## Summary
- Q3 revenue $217.6M (+25% YoY); net loss $37.9M vs $120.5M loss; Adjusted EBITDA $15.4M (+44%).
- Full-year 2022 guidance lowered: revenue $845-850M, Center Margin $229-232M, Adjusted EBITDA $50-53M.
- Ken Burdick appointed Chairman & CEO effective Sept 7, succeeding Michael Lester (remains strategic advisor).
- CFO transition: J. Michael Bruff to Business Transformation Officer; David Bourdon to become CFO Nov 10.
- Ended Q3 with $90.3M cash, $212.0M net debt; total clinicians 5,431 (+24% YoY).

## SEC filing metadata
- accession: 0000950170-22-023246
- form_type: 8-K
- ticker: LFST
- cik: 0001845257
- company_name: LifeStance Health Group, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845257/000095017022023246/0000950170-22-023246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845257/000095017022023246/lfst-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023246
- JSON: https://secwatch.observer/filing/0000950170-22-023246.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023246.txt

## Key facts
- Earnings Releases
  LifeStance Health Group, Inc. reported the quarter ended September 30, 2022 results: revenue $217.6 million, net income Net loss of $37.9 million. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2022
  - Revenue: $217.6 million
  - Net income: Net loss of $37.9 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: for the quarter ended September 30, 2022. (All results compared to prior-year comparative period, unless otherwise noted) Q3 2022 Highlights and FY 2022 Outlook • Revenue of $217.6 million increased $43.8 million or 25% compared to revenue of $173.8 million • Total clinicians of 5,431 up 24%, a net increase of 205 in the third quarter • Net loss of $37.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845257/000095017022023246/0000950170-22-023246-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.